Bulletin
Investor Alert

Topics

Food and Drug Administration

Video

Coronavirus Update: Trump Threatens to Permanently Cut Off Funding to WHO

  • Coronavirus Update: Trump Threatens to Permanently Cut Off Funding to WHO Coronavirus Update: Trump Threatens to Permanently Cut Off Funding to WHO 2:24
    Coronavirus Update: FDA Alert on Abbott Tests, NYSE to Reopen Trading Floor Coronavirus Update: FDA Alert on Abbott Tests, NYSE to Reopen Trading Floor 0:03
    How the U.S. Is Preparing for More Coronavirus Cases How the U.S. Is Preparing for More Coronavirus Cases 1:23
    How Coronavirus Test Kits Work How Coronavirus Test Kits Work 1:26
11:09 a.m. Today - By Mark Hulbert
Here’s a pandemic stock tip: Buy on the rumor of a COVID-19 vaccine, sell on the news Wall Street’s ‘smart money’ heads for the exit when retail buyers rush the doorWall Street’s ‘smart money’ heads for the exit when retail buyers rush the door, writes Mark Hulbert.
8:13 a.m. Today - MarketWatch.com
Cheap and fast screening tests could be a game-changer in fighting COVID-19 pandemicScreening tests with even moderate levels of accuracy can slow the spread of the coronavirus and help schools and workplaces reopen.
3:59 a.m. Today - Barrons.com
A Field Guide to Covid-19 Vaccines and Antivirals Canadian small-cap biotech CytoDyn has asked the FDA to grant the company’s drug, Leronlimab, an emergency-use authorization to treat mild to moderate Covid-19 cases.
6:10 p.m. Aug. 13, 2020 - By Associated Press
U.S. seizes virtual currency accounts that allegedly funded militant groupsThe Justice Department said Thursday that it has seized millions of dollars from cryptocurrency accounts that militant groups, including al-Qaida and the Islamic State, relied on to finance their organizations and violent plots.
5:38 p.m. Aug. 13, 2020 - Barrons.com
Why the Boom in India’s Pharmaceutical Stocks May Fade The Indian pharma stock surge dates to April, when the ban on exporting hydroxycholoroquine was lifted. The sector’s stocks jumped, but the gains won’t last as U.S. scrutiny returns.
1:33 p.m. Aug. 13, 2020 - Barrons.com
Why the Boom in India's Pharmaceutical Stocks May Fade The Indian pharma stock surge dates to April, when the ban on exporting hydroxycholoroquine was lifted. The sector's stocks jumped, but the gains won't last as U.S. scrutiny returns.
1:02 p.m. Aug. 13, 2020 - Barrons.com
How the 2020 Election Could Affect Health-Care Stocks Here’s how a Biden and a Trump administration are likely to differ on drug pricing, health insurance, and Covid-19 plans
3:36 a.m. Aug. 13, 2020 - By Tomi Kilgore
IGC's stock rallies again, after rocketing fourfold on record volume in the previous sessionShares of India Globalization Capital Inc. surged 26% in premarket trading Thursday, to extend the fourfold rocket ride in the previous session, as they head for an open at the highest level seen during regular-session hours since February 2019. On Wednesday, the stock soared 300.4% on record volume of 333.4 million shares, after the company said it received authorization from the U.S. Food and Drug Administration to initiate a Phase 1 trial of its investigational cannabinoid formulation for the treatment of mile-to-severe dementia resulting from Alzheimer's disease. The FDA did not respond to a . "We are excited with the progress made and that the FDA will allow the Company to initiate trial testing on human subjects using natural organic cannabis extracts," said IGC Chief Executive Ram Mukunda. IGC was in the news in 2018, as the stock soared after the company , or those containing cannabinoids. The stock was then , as the exchange said the company had engaged in operations that were "contrary to the public interest." The company said in February 2019 that it the exchange's decision to delist the stock. The stock has rallied more than fivefold (up 433.4%) over the past three months, while the S&P 500 has gained 19.9%.
3:06 p.m. Aug. 12, 2020 - By Quentin Fottrell
Dr. Fauci says Russia risks ‘hurting a lot of people’ by rushing coronavirus vaccine ‘Having a vaccine, and proving that a vaccine is safe and effective, are two different things,’ he told ABC News‘Having a vaccine, and proving that a vaccine is safe and effective, are two different things,’ he told ABC News.
7:52 a.m. Aug. 12, 2020 - By Quentin Fottrell
Dr. Fauci tells Americans to be mindful of these important limitations about any future coronavirus vaccine ‘You must never abandon the public-health approach,’ Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told a live streamed Q&A‘You must never abandon the public-health approach,’ Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told a live streamed Q&A.
6:18 a.m. Aug. 12, 2020 - Barrons.com
Moderna Joins the Ranks of U.S. Covid-Vaccine Deals It is the latest deal in the U.S.’s Operation Warp Speed plan to fast-track promising vaccine candidates.
4:38 a.m. Aug. 12, 2020 - By Ciara Linnane
Russia’s accelerated COVID-19 vaccine greeted with alarm as experts say Phase 3 trial is essential ‘The goal isn’t to be first, it’s to be first in a way that gives people faith in a vaccine’s safety,’ says one expertNews that Russia has registered the first vaccine to treat COVID-19 before starting and completing Phase 3 trials was greeted with alarm on Tuesday, with experts concerned it may come with safety issues that could stoke antivaccination and anti-science sentiment.
7:09 a.m. Aug. 11, 2020 - Barrons.com
Russia Registers a Coronavirus Vaccine The vaccine has been tested on animals and two groups of 38 humans each, far fewer than is required for approval of a drug by the FDA.
4:27 a.m. Aug. 10, 2020 - By Tomi Kilgore
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infectionsShares of Seres Therapeutics Inc. rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phase 3 trial of its SER-109 for recurrent C. difficile infections (CDI), or an infection of the colon. Trading volume ballooned to 7.1 million shares, compared with the full-day average of about 876,000 shares. Seres said the study showed that SER-109 resulted in a "highly statistically significant absolute decrease" in the proportion of patients who experienced a recurrence in CDI within 8 weeks of administration versus placebo. ""We are extremely pleased with these highly clinically meaningful SER-109 Phase 3 study results, greatly exceeding the statistical threshold provided by the [Food and Drug Administration]," said Chief Executive Eric Shaff. "Based on our prior discussions with the FDA, we believe this trial should provide the efficacy basis for submitting an application for product approval." The stock has rallied 34.5% year to date through Friday, while the iShares Nasdaq Biotechnology ETF has advanced 13.0% and the S&P 500 has gained 3.7%.
12:58 a.m. Aug. 10, 2020 - By Sherri Snelling
Could flu vaccines lower your risk of Alzheimer’s? Research sheds new light Two studies released at the Alzheimer’s Association conference indicate a possible connection between flu and pneumonia shots with reducing or delaying cognitive declineThe studies show ‘vaccines are strongly associated with lower prevalence of dementia,’ says one scientist.
9:02 a.m. Aug. 8, 2020 - By Steve Goldstein
The market is underpricing the possibility of a vaccine, Goldman Sachs strategists sayThe market is underpricing the possibility of a coronavirus vaccine, according to Goldman Sachs strategists.
6:40 a.m. Aug. 8, 2020 - By Jaimy Lee
FDA approves Roche's new spinal muscular atrophy drugRoche Holding AG said Friday that the Food and Drug Administration had approved Evrysdi, a treatment for spinal muscular atrophy in adults and most children. It's the second drug to be approved by the regulator to treat the rare disease. The therapy was developed by PTC Therapeutics Inc. and will be marketed by Genentech, a division of Roche. "We believe Evrysdi, with its favorable clinical profile and oral administration, may offer meaningful benefits for many living with this rare neurological disease," Roche's Levi Garraway said in a news release. A spokesperson said in an email that the treatment will cost about $340,000 per year, which is a lower price point than Biogen's Spinraza and AveXis Inc.'s Zolgensma; however the lower-than-expected price "could help increase market share and rapidity of adoption, though will produce lower revenue per patient than we had estimated," RBC Capital Markets' Brian Abrahams wrote in a note to investors. Since the start of the year, PTC's stock is down 0.4%, shares of Roche have gained 6.2%, and the S&P 500 is up 3.7%.
3:00 a.m. Aug. 8, 2020 - Barrons.com
A Huge Pension Sold Apple, Microsoft, and GE Stock. It Bought This Biotech. The largest fund in New Jersey’s embattled pension sold Apple, Microsoft, and GE stock in the second quarter. It also initiated a stake in biotech Moderna.
1:49 p.m. Aug. 7, 2020 - By Joy Wiltermuth
Dow, S&P 500 finish higher even as pandemic aid talks break down in DC without a deal Dow books 3.8% weekly gain, its biggest in 2 monthsMajor U.S. stock indexes closed higher Friday, except for the Nasdaq Composite Index, despite Washington’s failure to produce a last-minute coronavirus aid package before Congress takes a summer recess, leaving America’s economic recovery hanging in the balance.
11:39 a.m. Aug. 7, 2020 - By Stephenie Overman
The latest victim of COVID-19: Alzheimer’s research Clinical trials with human participants are needed to test new Alzheimer’s drugs or treatments to prevent, slow or cure the diseaseBefore the pandemic, researchers hoped this year would be a breakthrough for 6 million Americans with the disease.
9:14 a.m. Aug. 7, 2020 - By Ciara Linnane
Coronavirus update: Global case tally climbs above 19 million; U.S. death toll moves above 160,000 after 11 straight days with 1,000-plus fatalities Uber sees more revenue from food delivery than ride-hailing for the first timeThe number of confirmed cases of the coronavirus illness COVID-19 climbed above 19 million on Friday, the death toll rose above 715,000 and the U.S. death toll topped 160,000, after an 11th straight day in which more than 1,000 deaths were counted.
7:24 a.m. Aug. 7, 2020 - By Ciara Linnane
GW Pharma shares slide 12% after company swings to loss during pandemicShares of GW Pharmaceuticals PLC slumped 12% Friday, after the company swung to a loss in the second quarter, hurt by the effect of the coronavirus pandemic. The U.K. company is the only one to have U.S. Food and Drug Administration approval for a cannabis-based drug, Epidiolex, a treatment for severe forms of childhood epilepsy. The company posted a loss of $8.8 million, or 2 cents a share, for the quarter, after income of $79.7 million in the year-earlier period. Revenue rose to $121.3 million from $72.0 million. "We were pleased with the strength of U.S. Epidiolex sales in the second quarter in spite of the COVID-19 pandemic," Chief Executive Justin Gover said in a statement. Epidiolex sales came to $117.7 million. "Further, the recent approval and imminent launch of Epidiolex for the treatment of seizures associated with TSC provides a meaningful new opportunity to accelerate momentum through the second half of 2020 and beyond," he said. Leerink analyst Marc Goodman said the numbers were "solid" coming in the midst of the pandemic, and in line with management's guidance from its first-quarter conference call. "... we think GW executed through the volatility well, and thus we are surprised that the stock is down ~10% in the after market," he wrote in a Thursday note to clients. Leerink rates the stock as outperform with a $190 stock price target. Shares have gained 11% in the year to date, as the S&P 500 has gained 3.6%.
7:04 a.m. Aug. 7, 2020 - Barrons.com
Pfizer Will Help Gilead Make Its Covid-19 Treatment, Remdesivir The drug giant is one of the firms that will manufacture remdesivir, Gilead Sciences’ experimental antiviral that got emergency approval in May as a treatment for Covid-19.
5:56 a.m. Aug. 7, 2020 - Barrons.com
Biogen Is Spiking Because Its Alzheimer’s Drug Takes Another Step Toward Approval The Food and Drug Administration has granted priority review status to Biogen’s experimental Alzheimer’s disease drug aducanumab.
5:11 a.m. Aug. 7, 2020 - By Jaimy Lee
NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatmentThe National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people who have been hospitalized because of a COVID-19 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration granted an emergency use authorization to remdesivir in May, several clinical trials have been initiated that aim to pair the investigational therapy with other drugs to see if the combination can better treat severely ill COVID-19 patients. This includes pairing remdesivir with Eli Lilly & Co. and Incyte Corp. 's Olumiant. Roche Holding AG has also said its rheumatoid arthritis drug in combination with remdesivir.
4:55 a.m. Aug. 7, 2020 - By Jaimy Lee
Biogen's stock rallies 11% after FDA accepts application for experimental Alzheimer's drugShares of Biogen gained 11.7% in premarket trading on Friday after the company said the Food and Drug Administration (FDA) had accepted the application for the company's investigational, and , Alzheimer's disease treatment. The regulator is expected to make a decision whether or not to approve aducanumab by March 7. In early 2019, Biogen had shelved the experimental therapy after a futility analysis indicated the drug wouldn't meet the primary endpoints in clinical studies. Then, in October, the company surprised investors by resurfacing plans to pursue FDA approval of aducanumab. Biogen's stock is down 6.4% for the year, while the S&P 500 is up 3.6%.
4:10 a.m. Aug. 7, 2020 - By Jaimy Lee
Pfizer to help manufacture Gilead's remdesivirShares of Pfizer Inc. gained 1.0% in premarket trading on Friday after it announced that it will help manufacture Gilead Sciences Inc.'s COVID-19 treatment remdesivir as part of a multi-year agreement. Gilead's stock was up 0.6% on Friday before the market opened. This is a rare manufacturing deal between two of the world's largest drugmakers; "Together, we are more powerful than alone," Pfizer CEO Albert Bourla said in a news release. Remdesivir, which has received an emergency authorization from the Food and Drug Administration as a treatment for severely ill COVID-19 patients, has not been formally approved by the regulator. Since the start of the year, Pfizer's stock is down 2.3%, shares of Gilead have gained 5.9%, and the S&P 500 has rallied 3.6%.
3:26 a.m. Aug. 7, 2020 - By Nicole Lyn Pesce
People are going blind and dying from drinking hand sanitizer: CDC 15 adults were hospitalized in New Mexico and Arizona for drinking methanol-laced sanitizer, and four died 15 adults were hospitalized in New Mexico and Arizona for drinking methanol-laced sanitizer, and four died
3:24 a.m. Aug. 7, 2020 - By Ciara Linnane
Four ex-FDA commissioners urge U.S. to step up efforts to collect blood plasma for clinical trials as COVID-19 treatment ‘While vaccine development continues, it’s important to advance every promising treatment option to improve the odds for those who become sick,’ scientists write in op-edA group of four former U.S. Food and Drug Administration commissioners is arguing for the U.S. to step up efforts to collect blood plasma from patients who have recovered from the coronavirus illness COVID-19 and to push ahead with clinical trials.
2:00 a.m. Aug. 7, 2020 - Barrons.com
A Covid Vaccine Could Be Ready Sooner Than You Think One benefit of a higher infection rate is that it could speed the conclusion of vaccine tests now under way. The first results could come as early as October, analysts say.
12:45 p.m. Aug. 6, 2020 - By Victor Reklaitis
Trump reimposes tariffs on Canadian aluminum, directs U.S. government to buy ‘essential’ drugs from American companies President also says his staff is continuing to work on an order tied to payroll taxes, eviction protections, unemployment insurance and student loansPresident Donald Trump say he has reimposed some tariffs on Canadian aluminum and signed an executive order that requires the U.S. government purchase “essential” drugs from American companies.
4:13 a.m. Aug. 6, 2020 - Barrons.com
FDA Approves Glaxo’s First Homegrown Cancer Drug Since It Sold Cancer Pipeline Belantamab is the first in a new generation of multiple myeloma therapies.
3:41 a.m. Aug. 6, 2020 - Barrons.com
Barron’s Daily: Bezos Sells Amazon Stock and Raises $3 Billion. That’s Nothing. Trump and Biden change their convention plans (again), first top-level college sports team cancels 2020 season, drugmakers sign deals for vaccines, and other news to start your day.
2:15 a.m. Aug. 6, 2020 - By Jaimy Lee
Hahn: FDA won’t make regulatory decisions based on preprints or news releases ‘What we’ve seen during the pandemic is a lot of preprints and press releases,’ FDA commissioner Stephen Hahn said last week. ’We can’t make a decision based upon a preprint or a press release.’The COVID-19 pandemic has upended the long standing model for publishing clinical data as researchers and drugmakers race to share the latest findings about treatment and vaccine candidates at a time when case counts and deaths are still rising.
5:17 p.m. Aug. 5, 2020 - Barrons.com
Novavax Stock Soars. Analysts Say Its Covid-19 Vaccine Might Be the Best. The morning after Novavax released data on the first human trial of its Covid-19 vaccine, analysts are saying that the data looks extraordinarily promising.
11:27 a.m. Aug. 5, 2020 - By Associated Press
Coronavirus testing in the U.S. is dropping, even as deaths mount An Associated Press analysis stated that the number of tests per day dropped 3.6% over the past two weeksU.S. testing for the coronavirus is dropping even as infections remain high and the death toll rises by more than 1,000 a day, a worrisome trend that officials attribute largely to Americans getting discouraged over having to wait hours to get a test and days or weeks to find out the results.
11:27 a.m. Aug. 5, 2020 - Associated Press
Coronavirus testing in the U.S. is dropping, even as deaths mount An Associated Press analysis stated that the number of tests per day dropped 3.6% over the past two weeksU.S. testing for the coronavirus is dropping even as infections remain high and the death toll rises by more than 1,000 a day, a worrisome trend that officials attribute largely to Americans getting discouraged over having to wait hours to get a test and days or weeks to find out the results.
7:18 a.m. Aug. 5, 2020 - By Michael Brush
The stock market will be flying high in a year — for 2 simple reasons Big surprises on the vaccine front plus the impact of economic stimulus will fuel stocksHere’s what to invest in.
6:20 a.m. Aug. 5, 2020 - Barrons.com
Johnson & Johnson Signs $1 Billion U.S. Government Deal for Vaccine The agreement calls for the company to supply the U.S. 100 million doses if its vaccine is approved or wins emergency-use authorization from the FDA.
4:17 a.m. Aug. 5, 2020 - By Jaimy Lee
DBV discloses FDA concerns about experimental peanut allergy treatmentShares of DBV Technologies tumbled 8.5% in premarket trading on Wednesday, the day after the company said it had received a complete response letter from the Food and Drug Administration for its experimental peanut allergy treatment. The regulator asked for a new study stemming from its concerns about the efficacy of the Viaskin Peanut patch. "Given the uncertainty regarding the timeline for BLA resubmission, we are taking a conservative approach and pushing Viaskin Peanut launch out by two years," SVB Leerink's Joseph Schwartz wrote in a note to investors on Tuesday. In January the FDA approved Aiummune Therapeutics Inc.'s Palforzia, the first peanut allergy treatment. It is an oral immunotherapy. DBV's stock is down 76.2% since the start of the year, compared with the S&P 500 , which has gained 2.3%.
Browse topics:
Link to MarketWatch's Slice.